Lazard Asset Management LLC Raises Stake in Medpace Holdings, Inc. $MEDP

Lazard Asset Management LLC increased its holdings in Medpace Holdings, Inc. (NASDAQ:MEDP) by 28.0% during the 1st quarter, Holdings Channel.com reports. The institutional investor owned 25,640 shares of the company’s stock after buying an additional 5,602 shares during the period. Lazard Asset Management LLC’s holdings in Medpace were worth $12,312,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors also recently bought and sold shares of the business. BOKF NA lifted its stake in Medpace by 0.8% during the 3rd quarter. BOKF NA now owns 2,542 shares of the company’s stock valued at $1,307,000 after acquiring an additional 20 shares during the period. Valeo Financial Advisors LLC increased its stake in shares of Medpace by 5.0% in the fourth quarter. Valeo Financial Advisors LLC now owns 444 shares of the company’s stock worth $249,000 after acquiring an additional 21 shares during the period. UMB Bank n.a. raised its holdings in shares of Medpace by 5.6% during the fourth quarter. UMB Bank n.a. now owns 450 shares of the company’s stock worth $253,000 after purchasing an additional 24 shares during the last quarter. Schulhoff & Co. Inc. raised its holdings in shares of Medpace by 1.1% during the fourth quarter. Schulhoff & Co. Inc. now owns 2,202 shares of the company’s stock worth $1,237,000 after purchasing an additional 25 shares during the last quarter. Finally, Balefire LLC lifted its position in Medpace by 6.1% during the first quarter. Balefire LLC now owns 451 shares of the company’s stock valued at $217,000 after purchasing an additional 26 shares during the period. 77.98% of the stock is owned by hedge funds and other institutional investors.

Insider Activity

In other news, VP Susan E. Burwig sold 7,500 shares of the firm’s stock in a transaction dated Tuesday, July 28th. The stock was sold at an average price of $600.00, for a total transaction of $4,500,000.00. Following the sale, the vice president directly owned 62,984 shares in the company, valued at $37,790,400. This trade represents a 10.64% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO August J. Troendle sold 3,510 shares of Medpace stock in a transaction dated Tuesday, July 28th. The shares were sold at an average price of $600.01, for a total value of $2,106,035.10. Following the completion of the transaction, the chief executive officer owned 638,946 shares of the company’s stock, valued at approximately $383,373,989.46. This represents a 0.55% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold 31,087 shares of company stock worth $16,203,054 in the last ninety days. Company insiders own 20.50% of the company’s stock.

Medpace Stock Performance

Shares of NASDAQ MEDP opened at $585.49 on Thursday. The company’s fifty day moving average price is $501.76 and its 200 day moving average price is $493.30. Medpace Holdings, Inc. has a 1 year low of $373.00 and a 1 year high of $677.90. The company has a market capitalization of $16.34 billion, a PE ratio of 34.32, a price-to-earnings-growth ratio of 2.55 and a beta of 1.15.

Medpace (NASDAQ:MEDP) last released its quarterly earnings results on Wednesday, July 22nd. The company reported $4.25 EPS for the quarter, beating the consensus estimate of $3.98 by $0.27. Medpace had a net margin of 17.67% and a return on equity of 110.15%. The company had revenue of $707.33 million for the quarter, compared to analyst estimates of $689.51 million. During the same quarter last year, the business earned $3.10 earnings per share. The firm’s revenue was up 17.2% on a year-over-year basis. Medpace has set its FY 2026 guidance at 17.250-17.950 EPS. On average, equities analysts expect that Medpace Holdings, Inc. will post 17.54 EPS for the current year.

Analyst Upgrades and Downgrades

Several research firms have commented on MEDP. Mizuho upped their price target on shares of Medpace from $586.00 to $665.00 and gave the company an “outperform” rating in a report on Friday, July 24th. TD Cowen lifted their price objective on Medpace from $419.00 to $492.00 and gave the company a “hold” rating in a research note on Friday, July 24th. Truist Financial boosted their price objective on Medpace from $462.00 to $609.00 and gave the company a “hold” rating in a report on Friday, July 24th. Leerink Partners set a $620.00 target price on Medpace in a research note on Thursday, July 23rd. Finally, Royal Bank Of Canada raised their target price on Medpace from $484.00 to $692.00 and gave the stock an “outperform” rating in a report on Friday, July 24th. Two investment analysts have rated the stock with a Buy rating and eleven have assigned a Hold rating to the stock. Based on data from MarketBeat, the company has an average rating of “Hold” and an average target price of $584.18.

Medpace Company Profile

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.